Phase 3 trial of transplant recipients with refractory cytomegalovirus with/without resistance receiving maribavir or investigator-assigned therapies: Subgroup analyses of efficacy and safety by renal impairment

被引：0
|
作者：
Dadwall, S. [1 ]
Duarte, R. [2 ]
Ho, A. [3 ]
Kamar, N. [4 ]
Gu, J. [5 ]
Sundberg, A. [5 ]
机构：
[1] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
[3] Singapore Gen Hosp, Singapore, Singapore
[4] Toulouse Univ Hosp, Toulouse, France
[5] Takeda Dev Ctr Amer Inc, Lexington, MA USA
来源：
BONE MARROW TRANSPLANTATION | 2022年 / 57卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P307
引用
收藏
页码：268 / 269
页数：2
相关论文
共 18 条
  • [1] Subgroup Safety Analyses in Solid Organ Transplant (SOT) Recipients in a Phase 3 Trial of Maribavir (MBV) versus Investigator-Assigned Therapy (IAT) for Cytomegalovirus (CMV) Infection (Refractory with or without Resistance; R/R)
    La Hoz, R. M.
    Florescu, D.
    Kumar, D.
    Saliba, F.
    Gu, J.
    Sundberg, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S11 - S12
  • [2] Randomized Phase 3 Open-label Study of Maribavir vs Investigator-assigned Therapy for Refractory/resistant Cytomegalovirus Infection in Transplant Recipients: Subgroup Analyses of Efficacy by Organ
    Avery, R. K.
    Blumberg, E. A.
    Florescu, D.
    Kamar, N.
    Kumar, D.
    Wu, J.
    Sundberg, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 441 - 441
  • [3] Maribavir (MBV) versus Investigator-Assigned Therapy (IAT) for Refractory Cytomegalovirus (CMV) Infection (with or without Resistance) in Solid Organ Transplant (SOT) Recipients: Subgroup Safety Analysis of a Phase 3 Study.
    La Hoz, R. M.
    Florescu, D.
    Kumar, D.
    Saliba, F.
    Gu, J.
    Sundberg, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 353 - 353
  • [4] Healthcare resource utilization of maribavir versus investigator-assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial
    Hirji, Ishan
    Cocks, Kim
    Moreno-Koehler, Alejandro
    Sundberg, Aimee
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (03)
  • [5] Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results
    Pereira, Marcus
    Cervera, Carlos
    Kotton, Camille
    Sasadeusz, Joe
    Wu, Jackie
    Fournier, Martha
    Shardlow, Richard
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 7 - 8
  • [6] Phase 3 Study of Maribavir (MBV) vs. Investigator-Assigned Therapy (IAT) for Refractory/Resistant (R/R) Cytomegalovirus (CMV) Infection Post-Transplant: Analysis of Kidney Recipients and Renal Safety
    Shihab, Fuad S.
    Avery, Robin K.
    Blumberg, Emily
    Haririan, Abdolreza
    Wu, Jingyang
    Sundberg, Aimee K.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 17 - 17
  • [7] Impact of Dysgeusia on Transplant Recipients with Refractory Cytomegalovirus with/without Resistance Receiving Maribavir: Post-Hoc Analyses from a Phase 3 Randomized Trial.
    Silveira, F.
    Haider, S.
    Kaul, D.
    Witzke, O.
    Gu, J.
    Sundberg, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 931 - 932
  • [8] PHASE 3 OPEN-LABEL STUDY OF MARIBAVIR FOR REFRACTORY/RESISTANT CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS: SUBGROUP ANALYSES BY ORGAN TYPE
    Kamar, Nassim
    Avery, Robin K.
    Blumberg, Emily A.
    Florescu, Diana
    Kumar, Deepali
    Wu, Jingyang
    Sundberg, Aimee
    TRANSPLANT INTERNATIONAL, 2021, 34 : 46 - 46
  • [9] Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients
    Chou, Sunwen
    Alain, Sophie
    Cervera, Carlos
    Chemaly, Roy F.
    Kotton, Camille N.
    Lundgren, Jens
    Papanicolaou, Genovefa A.
    Pereira, Marcus R.
    Wu, Jingyang J.
    Murray, Rose Ann
    Buss, Neil E.
    Fournier, Martha
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (02): : 413 - 421
  • [10] Healthcare Resource Utilization in Transplant Recipients With Cytomegalovirus Infection Refractory to Prior Treatment With/Without Resistance Receiving Maribavir Versus Investigatorassigned Therapy: Exploratory Analysis of the Phase 3 SOLSTICE Trial
    Hirji, Ishan
    Cocks, Kim
    Moreno-Koehler, Alejandro
    Sundberg, Aimee
    TRANSPLANTATION, 2022, 106 (09) : S746 - S747
12